Three maytansinoids with strong cytotoxicities, dehydrotrewiasine, maytanbutine, and trewiasine, were isolated and identified from Trewia nudiflora, and maytanbutine was obtained from this plant for the first time. A quick, easy, cheap, effective, rugged, and safe (QuEChERS) extraction combined with high-performance liquid chromatography (HPLC) was established to determine the three maytansinoids in T. nudiflora. The effects of major factors on the extraction efficiency of the QuEChERS method were evaluated and the optimal conditions using acetonitrile-ethyl acetate (1:1, v/v) as the extraction solvent and PestiCarb as the clean-up sorbents were established. Compared with Soxhlet extraction (SE) and ultrasonic-assisted extraction (UAE), the QuEChERS method was easy-to-operate and afforded a cleaner extract. A phenomenex HyperClone BDS C column was used for HPLC analysis. Methanol-acetonitrile-water was chosen as mobile phase for gradient elution. Method validation showed that all analytes showed good linearity (r > 0.999) over the investigated ranges and satisfactory recoveries ranging from 95.0% to 105.0%. The developed QuEChERS-HPLC method was simple, efficient, and applicable to the determination of maytansinoids in T. nudiflora.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpba.2021.113993 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy.
Pharmaceuticals (Basel)
December 2024
Department "Pharmacology, Pharmacotherapy and Toxicology", Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria.
The present review provides a detailed and comprehensive discussion on antibody-drug conjugates (ADCs) as an evolving new modality in the current therapeutic landscape of malignant diseases. The principle concepts of targeted delivery of highly toxic agents forsaken as stand-alone drugs are examined in detail, along with the biochemical and technological tools for their successful implementation. An extensive analysis of ADCs' major components is conducted in parallel with their function and impact on the stability, efficacy, safety, and resistance profiles of the immunoconjugates.
View Article and Find Full Text PDFMaintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer.
Future Oncol
October 2024
Gynaecological Oncology Unit, Catholic University of Rome & Fondazione Policlinico Gemelli IRCCS, Rome, 00168,Italy.
Article Synopsis
- Platinum-sensitive ovarian cancer (PSOC) is commonly treated with platinum-based chemotherapy plus bevacizumab, but patients often face disease progression within a year, indicating a need for new treatment strategies.
- Mirvetuximab soravtansine-gynx (MIRV), an antibody-drug conjugate targeting folate receptor alpha, has shown promising results when used with bevacizumab, particularly in patients with high levels of FRα.
- The ongoing Phase III GLORIOSA trial aims to compare the effectiveness of MIRV plus bevacizumab against bevacizumab alone for patients with FRα-high PSOC after responding to previous treatment.
HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications.
J Pharm Biomed Anal
October 2023
Department of Innovative Technologies in Medicine and Dentistry, Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara "G. d'Annunzio", Via dei Vestini 31, Chieti 66100, Italy; Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara "G. d'Annunzio", Via dei Vestini 31, Chieti 66100, Italy.
The present study focuses on the development and validation of an HPLC-DAD methodology for the detection of a potent chemotherapeutic agent, Maytansinoid Ravtansine (DM4), and its metabolite, S-methyl-DM4 (S-Me-DM4), in plasma samples. Methodologically, after a simple protein precipitation with acetonitrile and after drying 1 mL of supernatant, the sample (suspended with N,N-Dimethylacetamide, DMA) was directly analyzed by HPLC under isocratic elution using a mobile phase comprising milliQ water and methanol (25:75, v:v), both acidified with 0.1 % v:v formic acid.
View Article and Find Full Text PDFSafety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Int J Gynecol Cancer
April 2023
ARENSIA Exploratory Medicine, Institute of Oncology Unit, Chisinau, Moldova.
Objectives: Anetumab ravtansine is an antibody-drug conjugate consisting of a fully human anti-mesothelin monoclonal antibody conjugated to cytotoxic maytansinoid tubulin inhibitor DM4. Mesothelin is highly expressed in ovarian cancer. This phase Ib study determines the safety, pharmacokinetics, and anti-tumor activity of anetumab ravtansine and pegylated liposomal doxorubicin in mesothelin-expressing platinum-resistant ovarian cancer.
View Article and Find Full Text PDFGlobal Regulator AdpA_1075 Regulates Morphological Differentiation and Ansamitocin Production in subsp. .
Bioengineering (Basel)
November 2022
State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China.
is a well-known producer of maytansinoid antibiotic ansamitocin P-3 (AP-3). Growth of in submerged culture was characterized by the formation of complex mycelial particles strongly affecting AP-3 production. However, the genetic determinants involved in mycelial morphology are poorly understood in this genus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!